These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6897368)

  • 1. Adjuvant CMF effect on site of first recurrence, and appropriate follow-up intervals, in operable breast cancer with positive axillary nodes.
    Valagussa P; Tess JD; Rossi A; Tancini G; Banfi A; Bonadonna G
    Breast Cancer Res Treat; 1981; 1(4):349-56. PubMed ID: 6897368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience.
    Velez-Garcia E; Moore M; Vogel CL; Marcial V; Ketcham A; Bartolucci A; Liu C; Smalley R
    Breast Cancer Res Treat; 1983; 3 Suppl():S49-60. PubMed ID: 6367861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy.
    Valagussa P; Tancini G; Bonadonna G
    Cancer; 1986 Oct; 58(7):1411-7. PubMed ID: 3755647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance.
    Bonadonna G; Rossi A; Valagussa P; Banfi A; Veronesi U
    Cancer; 1977 Jun; 39(6 Suppl):2904-15. PubMed ID: 326384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group.
    Wallgren A; Bernier J; Gelber RD; Goldhirsch A; Roncadin M; Joseph D; Castiglione-Gertsch M
    Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):649-59. PubMed ID: 8690630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) Trial.
    Vélez-García E; Carpenter JT; Moore M; Vogel CL; Marcial V; Ketcham A; Singh KP; Bass D; Bartolucci AA; Smalley R
    Eur J Cancer; 1992; 28A(11):1833-7. PubMed ID: 1389521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
    Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
    Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'.
    Demicheli R; Miceli R; Brambilla C; Ferrari L; Moliterni A; Zambetti M; Valagussa P; Bonadonna G
    Breast Cancer Res Treat; 1999 Feb; 53(3):209-15. PubMed ID: 10369067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
    Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
    Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
    J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles.
    Tancini G; Bonadonna G; Valagussa P; Marchini S; Veronesi U
    J Clin Oncol; 1983 Jan; 1(1):2-10. PubMed ID: 6366125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local recurrence after mastectomy and adjuvant CMF: implications for adjuvant radiation therapy.
    Rangan AM; Ahern V; Yip D; Boyages J
    Aust N Z J Surg; 2000 Sep; 70(9):649-55. PubMed ID: 10976894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement.
    Ung O; Langlands AO; Barraclough B; Boyages J
    J Clin Oncol; 1995 Feb; 13(2):435-43. PubMed ID: 7844606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil.
    Miles DW; Harris WH; Gillett CE; Smith P; Barnes DM
    Int J Cancer; 1999 Aug; 84(4):354-9. PubMed ID: 10404085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
    Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
    J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
    Mansour EG; Gray R; Shatila AH; Osborne CK; Tormey DC; Gilchrist KW; Cooper MR; Falkson G
    N Engl J Med; 1989 Feb; 320(8):485-90. PubMed ID: 2915651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.